Program
SIM0689
A development code. Also written as “SIM0689 for Injection”.
Its studies are mostly in Neoplasms, led by Simcere Pharmaceutical Group.
Furthest: phase 1, since Jun 10, 20261 company-led study, 1 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Simcere Pharmaceutical Group | 11 open or running | phase 1since Jun 10, 2026 | Jun 10, 2026 | Dec 2028phase 1 · NCT07660432 |
Also a collaborator on its studies: shanghai-xianwei-medical-technology-co-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2026First study: phase 1 study in NeoplasmsFirst studyNCT07660432 · 472 planned · China
Ahead
- Dec 2028Primary completion: phase 1 study in NeoplasmsNCT07660432
TargetBeta
VEGFA →read by rule
“SIM0689 for Injection is a Programmed Cell Death Protein 1(PD1) / Vascular Endothelial Growth Factor (VEGF) bispecific antibody.”study text, by rule · the study
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bevacizumabrule | Hoffmann-La Roche | phase 4 | 250 |
| Ranibizumabrule | Novartis | phase 4 | 108 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660432Neoplasms · China | 1 | Recruiting | Dec 2028 | 472 |
How it is read
Names in the registry
- “SIM0689 for Injection”, 1 entry
Codes read as this program: SIM0689.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.